30Oct
[Video] I Wish I Knew What I Know Now: Conversations with AGG on FDA Issues - Key Due Diligence Issues to Consider When Acquiring or Investing in Life Sciences Companies or Products
AGG is pleased to present the second episode in a podcast series titled, “I Wish I Know What I Know Now: Conversations with AGG on FDA Issues,” covering key due diligence issues to consider when acquiring or investing in life science companies or products. In this episode, AGG partner Alan G. Minsk and Brian A. Teras provides an overview of the diligence process, potential red flags, common mistakes, and other factors to consider during the due diligence process. Each month, we'll release a...
By:
Arnall Golden Gregory LLP
Related
Connecticut Governor Ned Lamont recently signed into law the Time’s Up Act (the “Act”), which ame...
Read More >
The FTC, and antitrust enforcement in general, are having their moment. For example, in early Januar...
Read More >
U.S. Citizenship and Immigration Services (USCIS) has instructed employers to continue using the cur...
Read More >
On Friday, January 10, the Department of Justice’s Antitrust Division and the Federal Trade Commiss...
Read More >
On September 18, 2019, California Governor Gavin Newsom signed into law AB5, codifying the ABC test ...
Read More >
Several years ago, a trend was emerging that consisted of third-party, private marketplaces where em...
Read More >